Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05708755RecruitingPhase 2
Monitoring immune response to CMV after lung transplant
This Phase 2 study monitors how your immune system reacts to CMV (a common virus) after a lung transplant. It may help doctors understand which patients are better protected and could guide future treatments to reduce CMV-related complications.
New York, New YorkAges 18–99 - NCT05706766Recruiting
Exercise coaching before stem cell transplant for multiple myeloma
This trial studies whether a structured exercise program before an autologous (your own cells) stem cell transplant can improve health and fitness in people with multiple myeloma. The goal is to safely prepare your body for transplant, and the study includes fitness testing and ongoing exercise training.
Boston, MassachusettsAges 18 years+ - NCT01241864RecruitingPhase 2
Islet transplant for type 1 diabetes after kidney transplant
This trial tests whether transplanting insulin-producing “islet” cells can better control blood sugar in people who have already received a kidney transplant. It’s mainly for adults with type 1 diabetes whose body is no longer making enough insulin, while they are on kidney-transplant medicines.
Chicago, IllinoisAges 18–68 - NCT02863692Recruiting
Registry study for chronic lymphocytic leukemia patients
This study is a registry that collects information about people with certain types of leukemia. It may help researchers understand the disease course and how patients are treated, including people who are newly diagnosed, currently treated, referred for transplant, or have relapsed.
Dresden, SaxonyAges 18 years+ - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Daphne, AlabamaAges 18 years+ - NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Bullhead City, ArizonaAges 18 years+ - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT05651828RecruitingEarly Phase 1
Tested adaptive dosing of vismodegib for advanced skin cancer
This trial tests an adaptive (adjusted) dosing plan using vismodegib for people with advanced basal cell carcinoma. It may help control the cancer while balancing side effects, and your team will closely monitor how your tumors respond.
Tampa, FloridaAges 18 years+ - NCT05672147RecruitingPhase 1
CD33 CAR T cells for hard-to-treat AML
This Phase 1 study tests a personalized immune-cell treatment (CD33 CAR T cells) for adults with AML that has returned or did not respond to treatment. It aims to see how safe the therapy is and how well it works for AML cells that carry the CD33 marker.
Duarte, CaliforniaAges 18 years+ - NCT05664126RecruitingPhase 2
Donor immune-cell treatment for stubborn CMV or adenovirus after transplant
This trial tests virus-fighting immune cells (T-cells) made from a donor to treat stubborn CMV or adenovirus infections after a blood and bone marrow transplant. It may help clear the virus when standard antiviral medicines are not working.
Memphis, TennesseeAges Up to 18 years - NCT05650749Enrolling by invitationPhase 1
GPC2 car T cells for neuroblastoma and retinoblastoma
This trial tests a new treatment using engineered immune cells (CAR T cells) that target a protein called GPC2 found on some cancer cells. It is for patients with high-risk neuroblastoma or metastatic retinoblastoma that has returned or not responded to other treatments.
Philadelphia, PennsylvaniaAges 1 year+ - NCT05660369RecruitingPhase 1
CAR T-cell treatment for EGFR-mutant glioblastoma
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
Boston, MassachusettsAges 18 years+ - NCT01630850Recruiting
Islet cell transplant for brittle type 1 diabetes
This trial studies whether transplanting insulin-producing islet cells can improve blood sugar control and reduce severe low blood sugar in people with “brittle” type 1 diabetes. It’s meant for adults with long-standing insulin dependence and troublesome, hard-to-control hypoglycemia.
Chicago, IllinoisAges 18–70 - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Orange, CaliforniaAges 18 years+ - NCT05628376Recruiting
Tracking lung cancer evolution through treatment
This study follows people with lung cancer over time to see how the disease changes, especially during and after treatment. By collecting tumor samples and blood tests every few months, researchers hope to understand why some cancers come back or become resistant, and find better ways to treat them.
LondonAges 18 years+ - NCT05600842Recruiting
Lower-dose radiation for HPV-positive throat cancer
This trial tests whether using a de-escalated (lower/intensity-reduced) radiation approach can treat HPV-positive oropharyngeal squamous cell carcinoma. It may help reduce side effects while still keeping the cancer under control.
Orange, CaliforniaAges 18 years+ - NCT05607108RecruitingPhase 2
Study drug for advanced lung cancer with a specific genetic change
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
Basking Ridge, New JerseyAges 18 years+ - NCT05634369RecruitingPhase 1/Phase 2
NK cell and chemotherapy trial for relapsed soft tissue sarcoma
This early-phase trial studies a type of immune cell treatment (NK cells) made from donor cells, given with chemotherapy drugs gemcitabine and docetaxel. It’s for children and young adults whose bone or soft tissue sarcoma has come back or hasn’t responded to prior treatment.
South Birmingham, AlabamaAges 2–40 - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Birmingham, AlabamaAges 18 years+ - NCT05613413RecruitingPhase 2
Maintenance cabozantinib plus pembrolizumab after lung cancer control
This trial tests whether continuing treatment with cabozantinib plus pembrolizumab after your metastatic squamous lung cancer responds (or is stable) can help people live longer and stay in control. It may be an option if your cancer has already shown it can respond to initial (first-line) treatment.
Chicago, IllinoisAges 18 years+ - NCT05561387RecruitingPhase 3
Drug combinations for newly diagnosed myeloma without transplant
This study compares different combinations of medicines for people newly diagnosed with multiple myeloma who cannot safely get a stem cell transplant. It aims to find which drug plan works best and is tolerable for people with “frail” or “intermediate fit” health.
Anchorage, AlaskaAges Any age - NCT05559645Recruiting
Targeted oral pill for EGFR-mutated advanced lung cancer
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05588388RecruitingPhase 2
Testing bevacizumab with chemo and immunotherapy for small cell lung cancer
This Phase 2 trial studies whether adding bevacizumab to chemo plus immunotherapy (including atezolizumab) can improve outcomes in extensive-stage small cell lung cancer (ES-SCLC) that has spread to the liver. It may help by blocking tumor blood vessel growth while boosting anti-cancer immune and treatment effects.
Los Angeles, CaliforniaAges Any age
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,550 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.